[Skip to Content]

Sublingual Dexmedetomidine for Agitation in Bipolar Disorder, SARS-CoV-2 Infection and Maternal Morbidity and Mortality, Neurological Outcome in Refractory Out-of-Hospital Cardiac Arrest, and more

JAMA
Published Online: February 22, 2022 Audio Editors' Summary 13 min 21 sec
<title>Sublingual Dexmedetomidine for Agitation in Bipolar Disorder, SARS-CoV-2 Infection and Maternal Morbidity and Mortality, Neurological Outcome in Refractory Out-of-Hospital Cardiac Arrest, and more</title>
Backward 15 Play Pause Forward 15
1x
0:00 / 0:00
Download MP3

Editor's Summary by Kristin Walter, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the February 22, 2022, issue.

Subscribe

Subscribe on your favorite podcast source to receive future episodes of this podcast.
Learn more about this JAMA Network podcast here

Related Articles

  1. Audio Highlights

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue